Evidence map›Paper›PMID 42806637›Full record

ArticleEuropean journal of immunology2026

A Novel Sulfatide Analog Recognized by Human iNKT Cells Enhances Polyfunctional Antigen-Specific CD8

Ayaka Hara, Julia DiSapio, Morgan Coombs, Seketoulie Keretsu, Svetlana Korinfskaya, Guzal Khayrullina, Vibhuti Joshi, Md Masud Alam, Hye Kim, Nargis Malik and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ayaka Hara *Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0009-0000-5421-1688
Julia DiSapio *Department of Chemistry, University of Connecticut, Storrs, Connecticut, USA.
Morgan CoombsLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Seketoulie KeretsuLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-9966-4883
Svetlana KorinfskayaLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-2624-0366
Guzal KhayrullinaLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Vibhuti JoshiLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Md Masud AlamLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Hye KimLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Nargis MalikLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Emily E SteffkeLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-3350-9818
Laila LatifiLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
John C HancockLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Jo D SpurgeonLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Byram H OzerNeuro-Oncology Branch, Center For Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Mark R GilbertNeuro-Oncology Branch, Center For Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Amy R HowellDepartment of Chemistry, University of Connecticut, Storrs, Connecticut, USA.
Masaki TerabeLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Funding

Immunological Analysis of Brain CancerZIABC011877 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TERABE, MASAKI · 2019 to 2025
$10.1M
Harnessing NKT Cell Activation by GlycolipidsR01GM111849 · NIGMS · UNIVERSITY OF CONNECTICUT STORRS · PI HOWELL, AMY · 2019 to 2022
$2.1M
CCR NIH HHS HHSN261200800001CCenter for Cancer Research, National Cancer Institute, National Institutes of Health Intramural Research Program ZIA BC 011877Intramural NIH HHS ZIA BC011877National Cancer Institute, National Institutes of Health HHSN261200800001ENCI NIH HHS NCT03018288NIGMS NIH HHS R01 GM111849NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Invariant natural killer T (iNKT) cells are CD1d-restricted T cells that recognize lipid antigens. Studies of analogs of a prototypic iNKT cell antigen, α-galactosylceramide (α-GalCer), have shown that ceramide structure affects the activities of mouse iNKT cells recognizing the antigen. However, the impact of antigen structure on human iNKT cell activities is less well studied. This study evaluated the antigenicity of eight novel synthetic sulfatide-based lipids with fluorobenzene at the acyl chain terminus and a variety of sphingoid base structures. Using CD1d-tetramers, we evaluated TCR recognition in ex vivo iNKT cells from healthy donors' peripheral blood mononuclear cells (PBMCs). One analog, SAP-3, was commonly recognized by iNKT cells from all donors. SAP-3 increased the proportion of CD69

Indexed as

CD8-Positive T-LymphocytesNatural Killer T-CellsSulfoglycosphingolipidsAnimalsAntigens, CD1dCells, CulturedGalactosylceramidesHumansInterferon-gammaInterleukin-2Leukocytes, MononuclearLymphocyte Activationalpha-galactosylceramideAntigens, CD1dGalactosylceramidesInterferon-gammaInterleukin-2SulfoglycosphingolipidsIL‐2iNKT cellssulfatide analogsvaccine adjuvant

Identifiers

PMID42806637
PMCPMC13625934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.